Mostrar el registro sencillo del ítem

dc.contributor.authorCuervo, Francy Milena
dc.contributor.authorSantos, Ana M.
dc.contributor.authorLondono, John
dc.contributor.authorAngarita, José Ignacio
dc.contributor.authorRueda, Juan C.
dc.contributor.authorGiraldo Bustos, Rodrigo
dc.contributor.authorBallesteros Muñoz, Jesús Giovanny
dc.contributor.authorSaldarriaga, EugeniaLucia
dc.contributor.authorPadilla Ortiz, Diana
dc.contributor.authorReyes Martinez, Viviana
dc.contributor.authorPeláez-Ballestas, Ingris
dc.contributor.authorDiaz Jiménez, Diana
dc.contributor.authorSantos Moreno, Pedro
dc.contributor.authorPinzón, Carlos E.
dc.contributor.authorCastañeda Orjuela, Carlos
dc.date.accessioned2023-04-14T17:47:38Z
dc.date.available2023-04-14T17:47:38Z
dc.date.issued2022
dc.identifier.citationCuervo FM, Santos AM, Londono J, Angarita JI, Rueda JC, Giraldo-Bustos R, Ballesteros-Muñoz JG, Saldarriaga EL, Padilla-Ortiz D, Reyes-Martinez V, Peláez-Ballestas I, Diaz-Jiménez D, Santos-Moreno P, Pinzón CE, Castañeda-Orjuela C. The burden of the most common rheumatic disease in Colombia. BMC Rheumatol. 2022 Jan 20;6(1):7. doi: 10.1186/s41927-021-00234-y. PMID: 35045891; PMCID: PMC8772222.es_CO
dc.identifier.issn2520-1026
dc.identifier.otherhttps://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-021-00234-y
dc.identifier.urihttp://hdl.handle.net/10818/54587
dc.description10 páginases_CO
dc.description.abstractBackground Estimating the burden of rheumatic diseases (RDs) requires proper evaluation of its lethal and nonlethal consequences. In Colombia, it is possible to find local data and Global Burden of Disease (GBD) reports that collect information from varied contexts and apply complex statistical models, but no on-site estimations are available. Methods This was a descriptive study on the burden of RD based on occurrence and mortality data in the general population during 2015, including information and prevalence estimations from the Community Oriented Program for the Control of Rheumatic Diseases (COPCORD) study. Disability-adjusted life years (DALYs) were estimated by combining measures of years of life lost (YLL) and years lived with disability (YLDs). For disability weight estimations among cases, different COPCORD responses were mapped using flowcharts to show the severity distribution according to GBD. All model parameters and results were validated through an expert consensus panel. Results Low back pain (LBP) was the RD with the greatest burden of disease, costing 606.05 (95% CI 502.76–716.58) DALYs per 100,000 inhabitants, followed by osteoarthritis (292.11; 95% CI 205.76–386.85) and rheumatoid arthritis (192.46, 95% CI 109.7–239.69). Conclusions The burden of RD is as high in Colombia as in other countries of the region. The results offer an interesting tool for optimizing healthcare system design as well as for planning the distribution of human and economic resources to achieve early diagnosis and adequate care of these diseases.en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherBMC Rheumatoles_CO
dc.relation.ispartofseriesBMC Rheumatol. 2022 Jan 20 6(1):7.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherBurden of diseaseen
dc.subject.otherRheumatoid arthritisen
dc.subject.otherLow back painen
dc.subject.otherOsteoarthritisen
dc.subject.otherColombiaen
dc.titleThe burden of the most common rheumatic disease in Colombiaen
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1186/s41927-021-00234


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International